News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

Update on NMD Pharma Clinical Trial

Nov 18, 2024 | CMT Research Updates

NMD Pharma, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, has announced that it has dosed the first Charcot-Marie-Tooth disease patient in its Phase 2a clinical trial of NMD670...

CMT Research Foundation Funds Project with Alloy Therapeutics’ 82VS to Test Novel RNA Therapeutics for Charcot-Marie-Tooth Disease

Nov 13, 2024 | CMT Research Updates, CMTRF Funded Research

The CMT Research Foundation has invested over $500,000 in a program led by 82VS, the venture studio of Alloy Therapeutics, Inc. to discover and develop novel Antibody Oligonucleotide Conjugate (AOC) therapeutics for CMT. Oligonucleotide therapeutics offer promise for...

Dr. Alessandra Bolino Completes Project Testing PIKfyve Inhibitor Drug from AcuraStem in CMT4B1 models

Nov 1, 2024 | CMT Research Updates, CMTRF Funded Research

Previous research from Dr. Alessandra Bolino demonstrated that inhibiting a protein called PIKfyve kinase could ameliorate some disease characteristics in CMT4B1 cells. In this project, Dr. Bolino partnered with AcuraStem to test one of their PIKfyve inhibitor drug...

Laura MacNeill Named New CEO of CMT Research Foundation

Oct 17, 2024 | Press Releases

The CMT Research Foundation has hired Laura MacNeill as Chief Executive Officer, it was announced today by Foundation Board Chair Peter de Silva. Ms. MacNeill succeeds Cleary Simpson, CEO for the past three years, who becomes Vice Chair of the Board. “Ms. MacNeill has...

CMT Research Foundation Surpasses $10 Million Goal of ENDGAME Capital Campaign

Oct 4, 2024 | Press Releases

The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease announced over the weekend at its annual Global CMT Research Convention that it has surpassed its goal of raising $10 million to fund research...

Actio Biosciences Receives Both Orphan Drug and Rare Pediatric Disease Designations From the FDA For Treatment of CMT2C

Aug 9, 2024 | CMT Research Updates, Drug Development

Actio Biosciences recently announced that they have received both orphan drug designation and rare pediatric disease designation for ABS-0871, a TRPV4 inhibitor, for the treatment of TRPV4+ Charcot-Marie-Tooth disease subtype 2C (CMT2C) from the U.S. Food and Drug...

Armatus Bio Completes Pivotal Animal Study Demonstrating Delivery, Safety, and Activity of Their CMT1A Gene Therapy and is Now Preparing to Advance Project to Clinical Trials

Jul 30, 2024 | CMT Research Updates, CMTRF Funded Research

Armatus Bio acquired the CMT1A gene therapy that was developed by Dr. Kleopas Kleopa and Dr. Scott Harper in a previous CMTRF-funded project to advance it further as a therapeutic. To demonstrate this therapy could be a safe and effective treatment for CMT1A, Armatus...

The CMT Research Foundation’s 2024 Global CMT Research Convention to Gather Renowned Scientific Experts and Patients to Discuss Status of Treatments and Cures for Charcot-Marie-Tooth Disease

Jul 18, 2024 | Press Releases

The CMT Research Foundation recently announced most of the speakers at its upcoming 2024 Global CMT Research Convention to be held September 26-28, in Cambridge, MA. On Thursday, September 26, CMTRF will host a Young Researcher Innovation Forum for CMT Research....

CMT Research Foundation to Launch Grant Program to Support Young Investigators Working on CMT

Jul 9, 2024 | Press Releases

The CMT Research Foundation announced that at its annual Global CMT Research Convention this September, it will host a Young Researcher Innovation Forum for CMT Research. The program will introduce the Young Researcher Innovation Grant and provide a platform to...

Augustine Therapeutics Raises $18.5 Million in a Series A First Closing

Jun 26, 2024 | CMT Research Updates, CMTRF Funded Research

The Charcot-Marie-Tooth Research Foundation participated in the $18.5 million Series A funding round recently announced by Augustine Therapeutics. The financing was led by Asabys Partners, with the participation of Eli Lilly & Company, CMTRF, and current investors...